Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has provided an announcement.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has received conditional approval from the National Medical Products Administration for its self-developed Class 1 innovative drug, Zeprumetostat Tablets. This drug is designed for adult patients with relapsed or refractory peripheral T-cell lymphoma who have undergone at least one prior systemic therapy. As the first domestically developed EZH2 inhibitor in China, this approval marks a significant milestone for the company, potentially enhancing its market position and offering new treatment options for patients.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$80.57 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a pharmaceutical company based in China, focusing on the development and marketing of innovative drugs. The company is known for its work in developing treatments for various medical conditions, with a particular emphasis on oncology and other critical therapeutic areas.
Average Trading Volume: 4,712,573
Current Market Cap: HK$478.6B
See more data about 1276 stock on TipRanks’ Stock Analysis page.